Related Experiment Video
Updated: Mar 12, 2026
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
Published on: September 29, 2014
IGF-1/GH axis enhances losartan treatment in Lama2-related muscular dystrophy
Anthony Accorsi1, Ajay Kumar1,2, Younghwa Rhee1
1Department of Health Sciences, Boston University, 635 Commonwealth Avenue, Boston, MA 02215, USA.
Abstract:
As the complexities of dystrophic pathology have been elucidated over the last few years, it has become increasingly clear that primary monogenetic defects result in multiple secondary pathologies capable of autonomously driving disease progression. Consequently, single-mode therapies fail to comprehensively ameliorate all aspects of pathology. Lama2-related muscular dystrophy (MDC1A) is a devastating congenital muscular dystrophy caused by mutations in the LAMA2 gene that results in multi-faceted secondary pathologies that include inflammation, fibrosis, apoptosis, and necrosis leading to severe muscle weakness and minimal postnatal growth. This study sought to implement a novel combinatorial treatment utilizing losartan, previously shown to ameliorate fibrosis and inflammation in conjunction with transgenic IGF-1 overexpression to improve postnatal growth. We found that dual-therapy rescued inflammation and fibrosis, improved weight gain, and led to remarkable restoration of muscle architecture and locomotory function in DyW mice (mouse model of MDC1A). We further showed using murine growth hormone that postnatal intervention with both therapies also yielded impressive amelioration of dystrophic pathology. Our results suggest for the first time that a combinatorial anti-fibrotic and pro-myogenic therapy could be the foundation of future therapies to a population of afflicted children in serious need.
Insights
This study combined losartan and IGF-1 therapy to treat Lama2-related muscular dystrophy (MDC1A). The dual-treatment significantly improved muscle structure, function, and growth in mice, offering hope for children with this condition.
Area of Science:
- Muscle Biology
- Genetics
- Therapeutic Development
Background:
- Primary monogenetic defects in muscular dystrophies cause multiple secondary pathologies, limiting single-mode therapy effectiveness.
- Lama2-related muscular dystrophy (MDC1A) involves LAMA2 gene mutations, leading to inflammation, fibrosis, apoptosis, and necrosis, causing severe muscle weakness.
- Current therapeutic approaches for MDC1A are insufficient to address the multifaceted nature of the disease.
Purpose of the Study:
- To investigate a novel combinatorial therapy for MDC1A using losartan and transgenic IGF-1 overexpression.
- To evaluate the efficacy of this dual-therapy in ameliorating secondary pathologies and improving muscle function in a mouse model of MDC1A.
- To explore the potential of combining anti-fibrotic and pro-myogenic strategies for treating congenital muscular dystrophies.
Main Methods:
- Utilized losartan, an anti-fibrotic and anti-inflammatory agent.
- Employed transgenic overexpression of Insulin-like Growth Factor 1 (IGF-1) to promote growth.
- Administered dual-therapy to DyW mice, a genetic model for MDC1A.
- Assessed outcomes including inflammation, fibrosis, weight gain, muscle architecture, and locomotory function.
Main Results:
- The combinatorial therapy effectively rescued inflammation and fibrosis in DyW mice.
- Significant improvements in weight gain and restoration of muscle architecture were observed.
- Remarkable recovery of locomotory function was achieved in treated mice.
- Postnatal intervention with both therapies also demonstrated impressive amelioration of dystrophic pathology.
Conclusions:
- A combinatorial anti-fibrotic and pro-myogenic therapy shows significant promise for treating MDC1A.
- This dual-treatment approach offers a potential foundation for future therapeutic strategies for children with MDC1A.
- Addressing multiple secondary pathologies concurrently is crucial for effective treatment of complex genetic muscle disorders.
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers